2022 Donald F. Klein Early Career Investigator Award

Click Here to Receive 2022 Award Information

 

ADAA offers an annual award to an early career investigator for the best original research paper on neurobiology, psychopharmacology, psychosocial treatments, or experimental psychopathology of anxiety disorders and depression. This award is named for Donald F. Klein, MD (1928-2019), who revolutionized psychiatric thinking through his discovery in the early 1960s that imipramine, a recently developed psychotropic medication, was effective in blocking panic attacks.

The Donald F. Klein award will be presented at the 2022 Denver Conference. The application form and more information will be posted here in the early summer of 2021. Sign up to receive updates about the 2022 Klein Award program.

"I am honored to have been selected as the ADAA Donald F. Klein Early Investigator 2021 awardee and to follow in the footsteps of so impressive a group of prior awardees. I am grateful to members of my Multimethod Affect and Cognition lab (MAClab) and to my graduate and postdoctoral mentors for the essential roles they have played in my path here. Consistent with the mission of ADAA, my long-term goal is to increase understanding of the mechanisms underlying emotional disorders, so that diagnosis and treatment can be improved and the suffering and cost associated with these disorders reduced. I look forward to sharing my work at the 2021 ADAA conference and to continued involvement with the organization." Annmarie MacNamara, PhD, 2021 Klein Winner

2022 Award Components

  • Complimentary registration to the 2022 ADAA Annual Conference (a $500 value)
  • Complimentary one year ADAA annual membership. Awardee(s) must present their research as a poster at the Annual Conference to be eligible for the complimentary membership.
  • Recognition at the Annual Conference
  • A $500 cash award
  • Selected paper will be seriously considered for publication with formal review in ADAA’s journal - Depression and Anxiety
  • Featured profile on the ADAA website

Award Eligibility

  • The award is restricted to investigators who have completed their terminal degree and are currently at a rank of assistant professor or below.
  • Individuals who are working to complete their degree are not eligible.
  • Willingness to host a professional webinar (recorded or live) within six months of winning the award on the research topic of the paper.
  • Applicants must be the first or senior author on the submitted paper, which must be original research on anxiety disorders, depression, and comorbid related disorders, focusing on neurobiology, psychosocial treatments, or experimental psychopathology.
  • The paper cannot be submitted or under review anywhere else from submission until notification about the award (including ADAA's Depression and Anxiety Journal).
  • ADAA recognizes, supports, and values the inclusion of diverse groups, educational backgrounds, and views and encourages award applications from minority groups. ADAA also encourages interdisciplinary as well as international applicants.
  • Note: ADAA Board Members and the ADAA Scientific Council members are not eligible.

Please note that the Klein award does not provide a travel or hotel allowance.

Thank you to our 2021 Klein Award Reviewers: Naomi Simon, MD, Msc and Charles B. Nemeroff, MD, PhD

Have a question about the Donald Klein award? Please email [email protected].


About Donald F. Klein

This award is named for Donald F. Klein, MD (1928-2019), who revolutionized psychiatric thinking through his discovery in the early 1960s that imipramine, a recently developed psychotropic medication, was effective in blocking panic attacks. Dr. Klein’s early contribution to the development of the DSM in large part gave birth to the modern branch of medical science dealing with the classification of disease of anxiety disorders. His early findings also heralded in the era of childhood anxiety disorders as biochemical disorders when he discovered that imipramine blocked childhood separation anxiety disorders.

In later years, Dr. Klein developed a compelling evolutionary-based hypothesis accounting for the etiology of panic disorders, which he terms “the false suffocation alarm theory of panic disorders.” His work remains relevant and topical to the present. Dr. Klein was the recipient of the 2005 ADAA Lifetime Achievement Award.

The Donald F. Klein Early Career Investigator Award is supported by Depression and Anxiety, the official journal of ADAA, published by Wiley-Blackwell, the scientific, technical, medical, and scholarly business of John Wiley & Sons, Inc.